Moderna CEO Bancel hits the gas with variant-specific boosters and a very early monkeypox program underway
As Moderna prepares two bivalent variant-specific Covid-19 boosters for delivery in the fall and looks into a potential monkeypox program, CEO Stéphane Bancel stressed on the Q2 call that “now is not the time to slow down.”
The company’s stock $MRNA soared more than 15% Wednesday morning, after Bancel reported a strong quarter and a new $3 billion share buyback plan. Covid sales took a dip compared to last quarter, coming in at $4.5 billion as opposed to $5.9 billion in Q1.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.